Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.

Canter DJ, Reid J, Latsis M, Variano M, Halat S, Rajamani S, Gurtner KE, Sangale Z, Brawer M, Stone S, Bardot S.

Eur Urol. 2019 Mar;75(3):515-522. doi: 10.1016/j.eururo.2018.10.028. Epub 2018 Oct 31.

2.

Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy.

Léon P, Cancel-Tassin G, Drouin S, Audouin M, Varinot J, Comperat E, Cathelineau X, Rozet F, Vaessens C, Stone S, Reid J, Sangale Z, Korman P, Rouprêt M, Fromond-Hankard G, Cussenot O.

World J Urol. 2018 Sep;36(9):1495-1500. doi: 10.1007/s00345-018-2290-y. Epub 2018 Apr 20.

PMID:
29679140
3.

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.

Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM.

Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23.

PMID:
29275435
4.

A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma.

Morgan TM, Mehra R, Tiemeny P, Wolf JS, Wu S, Sangale Z, Brawer M, Stone S, Wu CL, Feldman AS.

Eur Urol. 2018 May;73(5):763-769. doi: 10.1016/j.eururo.2017.12.002. Epub 2017 Dec 14.

PMID:
29249291
5.

Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.

Aramini B, Casali C, Stefani A, Bettelli S, Wagner S, Sangale Z, Hughes E, Lanchbury JS, Maiorana A, Morandi U.

Lung Cancer. 2016 Nov;101:82-87. doi: 10.1016/j.lungcan.2016.09.005. Epub 2016 Sep 6.

PMID:
27794412
6.

Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.

Koch MO, Cho JS, Kaimakliotis HZ, Cheng L, Sangale Z, Brawer M, Welbourn W, Reid J, Stone S.

Cancer Biomark. 2016 Jun 7;17(1):83-8. doi: 10.3233/CBM-160620.

7.

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL.

Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.

8.

Cell cycle progression score predicts metastatic progression of clear cell renal cell carcinoma after resection.

Askeland EJ, Chehval VA, Askeland RW, Fosso PG, Sangale Z, Xu N, Rajamani S, Stone S, Brown JA.

Cancer Biomark. 2015;15(6):861-7. doi: 10.3233/CBM-150530.

PMID:
26406412
9.

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).

Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, Jones J, Hartman AR, Meservey C, Jovanovic B, Helenowski I, Khan SA, Bethke K, Hansen N, Uthe R, Giordano S, Rosen S, Hoskins K, Von Roenn J, Jain S, Parini V, Gradishar W.

Breast Cancer Res Treat. 2015 Jun;151(3):629-38. doi: 10.1007/s10549-015-3435-y. Epub 2015 May 26.

PMID:
26006067
10.

Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.

Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.

Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.

11.

PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer.

Mithal P, Allott E, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Sangale Z, Lanchbury JS, Stone S, Freedland SJ.

Int J Urol. 2014 Dec;21(12):1209-14. doi: 10.1111/iju.12571. Epub 2014 Aug 5.

12.

Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy.

Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W, Graefen M, Sangale Z, Tikishvili E, Park J, Younus A, Gutin A, Lanchbury JS, Sauter G, Brawer M, Stone S, Schlomm T.

J Urol. 2014 Aug;192(2):409-14. doi: 10.1016/j.juro.2014.02.003. Epub 2014 Feb 7.

PMID:
24508632
13.

PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.

Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS.

Cancer Med. 2013 Aug;2(4):496-506. doi: 10.1002/cam4.97. Epub 2013 Jun 10.

14.

Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.

Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES.

Clin Cancer Res. 2013 Nov 15;19(22):6261-71. doi: 10.1158/1078-0432.CCR-13-0596. Epub 2013 Sep 18.

15.

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.

Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, Stone S.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):848-53. doi: 10.1016/j.ijrobp.2013.04.043. Epub 2013 Jun 5.

16.

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z; Transatlantic Prostate Group.

Br J Cancer. 2013 Jun 25;108(12):2582-9. doi: 10.1038/bjc.2013.248. Epub 2013 May 21.

17.

A robust immunohistochemical assay for detecting PTEN expression in human tumors.

Sangale Z, Prass C, Carlson A, Tikishvili E, Degrado J, Lanchbury J, Stone S.

Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):173-83. doi: 10.1097/PAI.0b013e3181f1da13.

PMID:
20930614

Supplemental Content

Loading ...
Support Center